Abstract
Diabetes mellitus is a devastating disease and the World Health Organization (WHO) expects that the number of diabetic patients will increase to 300 million by the year 2025. A variety of peptides, known as protein transduction domains (PTDs) or cell-penetrating peptides (CPPs), have been recently characterized for their ability to translocate into live cells. Some studies have shown that this technology is useful for the treatment of diabetes. In islet isolation and transplantation, cell-permeable peptides deliver anti-apoptotic molecules such as inhibitors of the c-Jun NH2-terminal kinases (JNKs) to protect islets. In type 2 diabetes, a cell-permeable peptide of JNK inhibitor markedly improves insulin resistance and ameliorates glucose tolerance in diabetic mice. JNKs are classic stress-activated protein kinases and many cellular stresses have been shown to stimulate JNK activation. In this review, we show some of the most recent contributions to the advancement of knowledge of the JNK pathway and several possibilities for the treatment of diabetes using protein transduction technology and the JNK inhibitory peptide.
Keywords: Diabetes, c-Jun NH2-terminal kinase, JNK inhibitor, protein transduction technology, cell-permeable peptide, cell penetrating peptide, islet transplantation, apoptosis
Current Bioactive Compounds
Title: Cell-Permeable Peptide Inhibitor of c-Jun NH2-Terminal Kinase for the Treatment of Diabetes
Volume: 6 Issue: 1
Author(s): Hirofumi Noguchi
Affiliation:
Keywords: Diabetes, c-Jun NH2-terminal kinase, JNK inhibitor, protein transduction technology, cell-permeable peptide, cell penetrating peptide, islet transplantation, apoptosis
Abstract: Diabetes mellitus is a devastating disease and the World Health Organization (WHO) expects that the number of diabetic patients will increase to 300 million by the year 2025. A variety of peptides, known as protein transduction domains (PTDs) or cell-penetrating peptides (CPPs), have been recently characterized for their ability to translocate into live cells. Some studies have shown that this technology is useful for the treatment of diabetes. In islet isolation and transplantation, cell-permeable peptides deliver anti-apoptotic molecules such as inhibitors of the c-Jun NH2-terminal kinases (JNKs) to protect islets. In type 2 diabetes, a cell-permeable peptide of JNK inhibitor markedly improves insulin resistance and ameliorates glucose tolerance in diabetic mice. JNKs are classic stress-activated protein kinases and many cellular stresses have been shown to stimulate JNK activation. In this review, we show some of the most recent contributions to the advancement of knowledge of the JNK pathway and several possibilities for the treatment of diabetes using protein transduction technology and the JNK inhibitory peptide.
Export Options
About this article
Cite this article as:
Noguchi Hirofumi, Cell-Permeable Peptide Inhibitor of c-Jun NH2-Terminal Kinase for the Treatment of Diabetes, Current Bioactive Compounds 2010; 6 (1) . https://dx.doi.org/10.2174/157340710790711746
DOI https://dx.doi.org/10.2174/157340710790711746 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effect of Pyrroloquinoline Quinone on Apoptosis and Autophagy in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Use of Double-source Computed Tomography for Evaluation of the Relationship Between Smoking and Coronary Plaques
Current Medical Imaging Cholesterol Subfraction Analysis in Patients with Acute Coronary Syndrome
Current Vascular Pharmacology Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension
Current Medicinal Chemistry BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients
Recent Patents on Anti-Cancer Drug Discovery Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology Emerging Technologies in Biocompatible Surface Modifying Additives: Quest for Physiologic Cardiopulmonary Bypass
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Angiotensin II Type I Receptor Blocker and Endothelial Function in Humans: Role of Nitric Oxide and Oxidative Stress
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Crocin Protects Human Umbilical Vein Endothelial Cells from High Glucose-Induced Injury Via Inhibiting the Endoplasmic Reticulum Stress Response
Current Molecular Medicine A Review on the Pharmacology and Toxicology of Steviol Glycosides Extracted from Stevia rebaudiana
Current Pharmaceutical Design Nutritional Interventions and Primary Prevention of Type 2 Diabetes
Current Nutrition & Food Science Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists
Current Pharmaceutical Design Scintigraphic Imaging of Inflammatory Processes
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) Vasotrophic Regulation of Age-Dependent Hypoxic Cerebrovascular Remodeling
Current Vascular Pharmacology Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes
Current Diabetes Reviews Computational and Experimental Approaches to Design Inhibitors of Amylin Aggregation
Current Drug Targets